| Entries |
| Document | Title | Date |
|---|
| 20100261653 | Polypeptide compounds for inhibiting angiogenesis and tumor growth - In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases. | 10-14-2010 |
| 20100261654 | COMPOSITIONS AND METHODS FOR INCREASING VASCULARIZATION - Disclosed are methods of increasing vascularization in a tissue by administering a neublastin polypeptide to a mammal exhibiting impaired or inadequate blood flow in the tissue. The methods can be used to in the treatment or prevention of a disorder characterized by impaired or inadequate blood flow or to increase vascularization in an organ that has been transplanted into a subject. | 10-14-2010 |
| 20100279937 | Method of Inhibiting Angiogenesis, Tumorigenesis and Cathepsin Activity - Insulin-like growth factor binding proteins (IGFBPs) and variants thereof, including IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, IGFBP-6 and the C-terminal fragments thereof, inhibit angiogenesis, tumorigenesis and cathepsin activity, particularly cathepsin B activity. | 11-04-2010 |
| 20110009323 | NON-IMMUNOGLOBULIN ANTIGEN BINDING SCAFFOLDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH - In certain embodiments, this present invention provides polypeptide or nucleotide non-immunoglobulin antigen binding scaffold compositions, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases. | 01-13-2011 |
| 20110028395 | PEPTIDE MODULATORS OF ANGIOGENESIS AND USE THEREOF - The invention generally features compositions and methods that are useful for modulating blood vessel formation, as well as methods that provide for the systematic and efficient identification of angiogenesis modulators. As described in more detail below, a systematic computational methodology based on bioinformatics was used to identify novel peptide modulators of angiogenesis that have been characterized in vitro and/or in vivo. | 02-03-2011 |
| 20110034387 | POLYPEPTIDE INHIBITING ANGIOGENESIS AND APPLICATION THEREOF - Provided is a low molecular polypeptide that can inhibit angiogenesis consisting of amino acid sequence YRGKKA, which is same to one portion sequence in apolipoprotein (a) Kringle V. Also provided are pharmaceutical composition and the uses for preventing or treating diseases relating to angiogenesis. | 02-10-2011 |
| 20110039779 | IGF-1R BINDING PROTEINS AND ANTAGONISTS - The present invention is drawn to new peptides and proteins that bind to human insulin-like growth factor-1 receptor (HIGF-IR), as well as nucleic acids encoding the same, vectors and cells comprising such nucleic acids, pharmaceutical compositions comprising such compounds, and methods of using any thereof, are provided. | 02-17-2011 |
| 20110053849 | REGULATION OF LITAF MODULATED CYTOKINE PRODUCTION BY A NOVEL P53 SHORT PEPTIDE - The present invention relates to a novel isolated and purified peptide of the sequence KQSQHMT [SEQ ID NO: 1], nucleic acid sequences encoding said peptide sequence and capable of expressing said sequence as an exogenous protein in a target cell; as well as methods for the reduction or inhibition of LITAF activity by transfecting the peptide KQSQHMT [SEQ ID NO: 1] or a nucleic acid capable of expressing said peptide, into a target cell. The present invention also relates to the use of the novel peptide (and corresponding nucleotide sequences) of the present invention for the regulation of cytokine expression in target cells. The present invention also relates to the use of the novel peptide (and corresponding nucleotide sequences) of the present invention for the regulation of inflammatory responses in mammals. | 03-03-2011 |
| 20110053850 | DOC1 COMPOSITIONS AND METHODS FOR TREATING CANCER - A purified DOC1 polypeptide comprising a fragment of SEQ ID NO: 1 is provided, wherein the DOC1 polypeptide is not the full-length DOC1 polypeptide sequence. A method of inhibiting angiogenesis in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting angiogenesis. A method of inhibiting tumor growth in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell in the subject produces the DOC1 polypeptide, thus inhibiting tumor growth. | 03-03-2011 |
| 20110065640 | ANTI-INVASIVE AND ANTI-ANGIOGENIC COMPOSITIONS - A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivates, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and/or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and/or angiogenesis. The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors. | 03-17-2011 |
| 20110065641 | POLYPEPTIDE AND DNA THEREOF USEFUL AS A NEOVASCULAR MARKER - A marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive system disease, central nervous system disease and cancer, the method of detection of the marker and a diagnosis kit of the diseases are provided. Additionally, therapeutic agents of the diseases are provided. | 03-17-2011 |
| 20110071082 | LONG LASTING ANTI-ANGIOGENIC PEPTIDES - Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect. | 03-24-2011 |
| 20110077201 | HIGH AFFINITY VEGF-RECEPTOR ANTAGONISTS - A cell-based screen is reported can be used to identify specific receptor-binding compounds in a combinatorial library of peptoids (N-alkylglycine oligomers) displayed on beads. This strategy was applied to the isolation of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)-binding peptoids, which were optimized to create lead compounds with high affinity for VEGFR2. One of these peptoids was shown to be an antagonist of VEGF-VEGFR2 interaction and receptor function. | 03-31-2011 |
| 20110092427 | POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING THE POLYPEPTIDE - Disclosed is a novel polypeptide which can inhibit angiogenesis. Also disclosed is use of the polypeptide. The polypeptide comprises at least one amino acid sequence selected from the amino acid sequences depicted in SEQ ID NOs: 1-3, is composed of 120 or less amino acid residues, and has an anti-angiogenic activity. The polypeptide has an anti-angiogenic activity, has a lower molecular weight compared with that of PEDF, and has excellent penetration or absorption into a living body, particularly an affected part in a living body. | 04-21-2011 |
| 20110098224 | PROTEIN KINASE C PEPTIDE MODULATORS OF ANGIOGENESIS - The present invention provides peptides for inhibiting various protein kinase C isozymes. The peptide can be directed to any region of the protein kinase C isozyme, and in one embodiment, is directed to the V5 domain. The peptide can be conjugated to a carrier, in a releasable or non-releasable manner. The peptides can be used to inhibit angiogenesis and/or vascular permeability. The peptides can be used to treat subjects having, for example, cancer, diabetic blindness, macular degeneration, rheumatoid arthritis, or psoriasis. | 04-28-2011 |
| 20110118185 | AMINO ACID SEQUENCES DIRECTED AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF CONDITIONS AND DISEASES CHARACTERIZED BY EXCESSIVE AND/OR PATHOLOGICAL ANGIOGENESIS OR NEOVASCULARIZATION - The present invention relates to amino acid sequences that are directed against vascular endothelial growth factor (VEGF), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization. | 05-19-2011 |
| 20110124564 | NUCLEOLIN-BINDING PEPTIDES, NUCLEOLIN- BINDING LYTIC PEPTIDES, FUSION CONSTRUCTS AND METHODS OF MAKING AND USING SAME - The invention relates to nucleolin binding peptides, nucleolin binding peptides and anti-nucleolin antibody conjugates with cytotoxic activity, fusion constructs, methods of using nucleolin binding peptides and antibodies and fusion constructs thereof, and methods of treating various disorders, undesirable conditions and diseases treatable with nucleolin binding peptides and fusion constructs, such as undesirable or aberrant cell proliferation (hyperproliferation) or hyperproliferative disorders, including tumors, cancers, neoplasia and malignancies, angiogenesis related or dependent diseases, and inflammatory diseases and inflammation. | 05-26-2011 |
| 20110144022 | Anti-Angiogenic Peptide - The invention relates to an anti-angiogenic peptide corresponding to a fragment of angiostatin molecule, pharmaceutical compositions containing it and the use thereof in the preventive or therapeutic treatment of diseases involving angiogenesis. | 06-16-2011 |
| 20110152192 | Compositions and Methods for the Treatment of Angiogenesis-Related Eye Diseases - The invention generally relates to compositions and methods of treatment and/or prevention of angiogenesis-related eye diseases using low doses of rhodostomin variants, and in particular, low doses of a fusion protein comprising a rhodostomin variant, wherein the rhodostomin variant is conjugated with a variant of Human Serum Albumin (HSA) where the cysteine residue at position 34 of the HSA amino acid sequence has been replaced with serine. | 06-23-2011 |
| 20110152193 | INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ DOMAINS - This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins. | 06-23-2011 |
| 20110195901 | ARTERY- AND VEIN-SPECIFIC PROTEINS AND USES THEREFOR - Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example. | 08-11-2011 |
| 20110195902 | Fusion Protein Composed of Matrix Metalloproteinase-2 Inhibitor Peptide Derived From Amyloid-B Precursor Protein and Tissue Inhibitor of Metalloproteinase-2 - The present invention provides an agent capable of inhibiting MMP-2 specifically. Disclosed is a fusion molecule composed of a β-amyloid precursor protein molecule-derived domain having an activity of selectively inhibiting matrix metalloproteinase-2 and a tissue inhibitor of metalloproteinase capable of binding to latent matrix metalloproteinase. Also disclosed are a pharmaceutical composition, a cancer metastasis and/or angiogenesis inhibitor, a therapeutic and/or prophylactic for cardiovascular diseases, and a matrix metal loproteinase-2 inhibitor, each of which comprises the fusion molecule. | 08-11-2011 |
| 20110207667 | EFFICIENT EXPRESSION OF TRUNCATED HUMAN RNASET2 IN E. COLI - An isolated, recombinant truncated human RNASET2 having anti-angiogenic properties, methods for efficient expression thereof in bacteria and therapeutic uses thereof. | 08-25-2011 |
| 20110207668 | BINDING PROTEINS INHIBITING THE VEGF-A RECEPTOR INTERACTION - The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration. | 08-25-2011 |
| 20110218150 | ANTIANGIOGENIC POLYPEPTIDES AND METHODS FOR INHIBITING ANGIOGENESIS - Conjugated kringle protein fragments are disclosed as compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed. | 09-08-2011 |
| 20110230410 | LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY - The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided. | 09-22-2011 |
| 20110245175 | INHIBITING INTERACTION BETWEEN THE HIF-1ALPHA AND p300/CBP WITH HYDROGEN BOND SURROGATE-BASED - The present invention relates to peptides having one or more stable, internally constrained α-helices, and that include a sequence that mimics at least a portion of the C-terminal transactivation domain of HIF-1α. Also disclosed are pharmaceutical compositions containing these peptides and methods of using these peptides, for example to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF-1α with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, decrease cell survival and/or proliferation, and identify potential ligands of CREB-binding protein and/or p300. | 10-06-2011 |
| 20110257100 | Inhibitors of Protein Tyrosine Kinase Activity - This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions. | 10-20-2011 |
| 20120083445 | Compositions Containing HC-HA Complex and Methods of Use Thereof - Disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of IαI, wherein the transfer of the heavy chain of IαI is catalyzed by TSG-6. Further disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of IαI, wherein the transfer of the heavy chain of IαI is catalyzed by the TSG-6 like protein. Additionally, disclosed herein are methods of manufacturing said complex and methods of use thereof | 04-05-2012 |
| 20120088727 | RSPONDINS AS MODULATORS OF ANGIOGENESIS AND VASCULOGENESIS - The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2 are angiogenesis promoters, and the identification of Rspo2 and 3 as positive regulators of vascular endothelial growth factor (VEGF). These results indicate a major role for Rspondins, particularly Rspo3 and/or Rspo2 in the signalling system during angiogenesis. The invention also relates to the use regulators or effectors or modulators of Rspondin3, including agonists and antagonists, in the treatment of conditions where treatment involves inhibiting or promoting angiogenesis and/or vasculogenesis. | 04-12-2012 |
| 20120101040 | ANGIOGENESIS INDUCING AGENT COMPRISING RECOMBINANT GELATIN - An object of the present invention is to provide a biologically safe and highly bioadhesive angiogenesis inducing agent. The present invention provides an angiogenesis inducing agent which comprises a recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen. | 04-26-2012 |
| 20120115783 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides novel peptidomimetic macrocycles and methods of using such macrocycles for the treatment of disease. | 05-10-2012 |
| 20120129775 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE - Methods of inhibiting undesired angiogenesis are provided, which methods include administering to a subject a therapeutically effective amount of at least one of the compounds described herein, or a pharmaceutically acceptable salt thereof. | 05-24-2012 |
| 20120157384 | MUTANTS PF4 POLYPEPTIDES EXHIBITING AN INCREASED ANTI-ANGIOGENIC ACTIVITY - The present invention pertains to PF4 muteins which comprise a substitution at position 67, e.g. a L67H substitution, compared to the sequence of the wild-type PF4 protein. Such PF4 muteins exhibit an increased anti-angiogenie activity and a reduced affinity for proteoglycans compared to the wild-type PF4 protein. | 06-21-2012 |
| 20120178690 | NOVEL NETRIN DERIVATIVES AND USES THEREOF - Netrin proteins and their receptors regulate cell and axon migration, and are implicated in tissue morphogenesis, tumorigenesis and angiogenesis. Deregulation of mechanisms that control cell motility plays a key role in tumor progression by promoting tumor cell dissemination. Unwanted neovascularization also contributes to tumor progression and metastasis and to ocular diseases which are a leading cause of blindness. Here, we describe novel netrin-derived polypeptides and fragments or derivatives thereof that selectively inhibit cell growth, migration or branching. Methods and compositions for the treatment and prevention of conditions involving cell migration or neovascularization, such as cancer and ocular disease, are also provided. | 07-12-2012 |
| 20120196805 | COMPOSITIONS AND METHODS TO CONTROL ANGIOGENESIS WITH CUPREDOXINS - The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development. | 08-02-2012 |
| 20120208757 | USE OF HYALURONAN FOR PROMOTING ANGIOGENESIS - Use of hyaluronan, either alone or in combination with collagen, for promoting angiogenesis. | 08-16-2012 |
| 20120232012 | COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF - The invention generally features compositions and methods that are useful for modulating blood vessel formation, as well as methods that provide for the systematic and efficient identification of angiogenesis modulators. As described in more detail below, a systematic computational methodology based on bioinformatics was used to identify novel peptide modulators of angiogenesis that have been characterized in vitro and/or in vivo. | 09-13-2012 |
| 20120283188 | GENES AND PROTEINS ASSOCIATED WITH ANGIOGENESIS AND USES THEREOF - Disclosed is a panel of biomarkers associated with angiogenesis, and the use of such biomarkers (genes, proteins, homologues and analogs thereof) to regulate angiogenesis. Methods for identifying compounds useful for regulating angiogenesis and conditions related thereto are disclosed. | 11-08-2012 |
| 20120295851 | PEPTIDES, COMPOSITIONS AND USES THEREOF - Described is an N-terminal hexapeptide fragment of maximakinin, QUB 698.8, which exhibits potent tissue selective actions on smooth muscle. It demonstrates a high degree of selectivity for arterial smooth muscle over small intestinal smooth muscle, causing potent relaxation of arterial smooth muscle, while causing less potent contraction of ileal smooth muscle. It may be used treatment of diseases of the cardiovascular system and in promotion of angiogenesis. | 11-22-2012 |
| 20120316115 | METHODS AND COMPOSITIONS FOR INHIBITING ANGIOGENESIS - The present invention relates to methods and compositions for modulating angiogenesis. In particular, the present invention relates to Pigment Epithelial-derived Factor (PEDF) fragments for use in modulating angiogenesis and treating angiogenesis mediated disease. | 12-13-2012 |
| 20130023479 | USE OF NUCLEOLIN AS A BIOMARKER FOR LYMPHANGIOGENESIS IN CANCER PROGNOSIS AND THERAPY - The present invention relates to a method of identifying cancer subjects, in particular human patients, who are suitable for anti-lymphangiogenesis therapy to prevent tumor growth and tumor metastasis. The present invention also relates to a new approach, which uses nucleolin as a bait to search and screen for lymphangiogenesis inhibitors or cancer suppressors, which function in a manner that is analogous to endostatin. The invention is based upon the discovery that nucleolin is specifically expressed on lymphangiogenic vessels and functions as a specific receptor for endostatin, and thus is involved in the signal transduction pathway of endostatin as an anti-lymphangiogenesis inhibitor. The present invention also discloses that cell surface nucleolin on lymphatic endothelial cells is a biomarker for lymphangiogenic vessels, which could be used for the prediction of tumor metastasis. | 01-24-2013 |
| 20130045922 | PRO-ANGIOGENIC FRAGMENTS OF PROMININ-1 AND USES THEREOF - Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these pep tide analogs and uses thereof. | 02-21-2013 |
| 20130053319 | CHEMOKINE DERIVED PEPTIDES AND USES FOR CHRONIC WOUND AND ANGIOGENESIS INHIBITION TREATMENTS - Disclosed are peptides having activity against receptor CXCR3 are disclosed that exhibit activity in preventing the formation of new vessels and activity in mediating the dissociation of newly-formed vessels and resolving of wounds in the later stages of wound healing. Preferred peptides are derived from the α-helix portion IP-10 (CXCL10) or from IP-9 (CXCL11), are nontoxic, and smaller than naturally occurring peptides, making them useful in therapies against diseases or disease states marked by unwanted angiogenesis, including tumorogenic diseases such as cancers, and in healing of chronic wounds. | 02-28-2013 |
| 20130059782 | PHOSPHOLIPID-ENRICHED VESICLES BEARING TISSUE FACTOR HAVING HAEMOSTATIC ACTIVITIES AND USES THEREOF - The invention relates to a method for improving the procoagulant properties of TF expressed in eukaryotic cells by contacting microvesicles derived from said eukaryotic cells with a negatively-charged phospholipid such as phosphatidylserine. The invention also relates to microvesicles obtained using said method as well as to the uses thereof as procoagulant agents, for wound healing and for promoting angiogenesis. | 03-07-2013 |
| 20130072432 | PTD-UQCRB FUSION POLYPEPTIDE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ISCHEMIC DISEASES, CONTAINING SAME - A PTD-UQCRB fusion polypeptide, and a pharmaceutical composition for preventing and treating ischemic diseases, containing the same. The PTD-UQCRB fusion polypeptide of the present invention very effectively passes through a cell membrane to induce angiogenesis and does not cause cytotoxicity, and is thus useful for preventing and treating ischemic diseases. | 03-21-2013 |
| 20130085108 | PEPTIDES FOR PROMOTING ANGIOGENESIS AND AN USE THEREOF - The present invention relates to a peptide promoting angiogenesis and novel use thereof. More particularly, the invention relates to peptides promoting angiogenesis, and the use of the peptide for promoting angiogenesis and preventing or treating angiogenesis-related disease. The peptide of the present invention have an excellent effect on promoting angiogenesis. Accordingly, it is useful for preventing or treating angiogenesis-related disease and for preparing regeneration of skin flap, wound and burn healing, implantation of artificial-skin and preparation of blood vessels for transplantation. | 04-04-2013 |
| 20130102534 | COMPOSITIONS AND METHODS FOR TREATING PATHOLOGIC ANGIOGENESIS AND VASCULAR PERMEABILITY - Compounds, compositions and methods for inhibiting vascular permeability and pathologic angiogenesis are described herein. Methods for producing and screening compounds and compositions capable of inhibiting vascular permeability and pathologic angiogenesis are also described herein. Pharmaceutical compositions are included in the compositions described herein. The compositions described herein are useful in, for example, methods of inhibiting vascular permeability and pathologic angiogenesis, including methods of inhibiting vascular permeability and pathologic angiogenesis induced by specific angiogenic, permeability and inflammatory factors, such as, for example VEGF, bFGF and thrombin. Methods for treating specific diseases and conditions are also provided herein. | 04-25-2013 |
| 20130137637 | PEPTIDES FOR PROMOTING ANGIOGENESIS AND AN USE THEREOF - The present invention relates to a peptide promoting angiogenesis and novel use thereof. More particularly, the invention relates to peptides promoting angiogenesis, and the use of the peptide for promoting angiogenesis and preventing or treating angiogenesis-related disease. The peptide of the present invention have an excellent effect on promoting angiogenesis. Accordingly, it is useful for preventing or treating angiogenesis-related disease and for preparing regeneration of skin flap, wound and burn healing, implantation of artificial skin and preparation of blood vessels for transplantation. | 05-30-2013 |
| 20130150298 | PARSTATIN PEPTIDES - The present invention relates to parstatin peptides, compositions comprising parstatin peptides and their use in the treatment of various disorders, including angiogenesis-related diseases, ocular neovascularisation and related disease states, ischemia-reperfusion injury and myocardial-related disease states, and renal disorders. | 06-13-2013 |
| 20130150299 | TEMPLATE-FIXED PEPTIDOMIMETICS - The template-fixed β-hairpin peptidomimetics Cyclo(-Tyr-His-X-Cys-Ser-Ala- | 06-13-2013 |
| 20130150300 | SPECIFIC BINDING SITES IN COLLAGEN FOR INTEGRINS AND USE THEREOF - The present invention identified a high affinity binding sequence in collagen type III for the collagen-binding integrin I domains. Provided herein are the methods used to characterize the sequence, the peptides comprising this novel sequence and the use of the peptides in enabling cell adhesion. Also provided herein are methods to identify specific integrin inhibitors, sequences of these inhibitors and their use in inhibiting pathophysiological conditions that may arise due to integrin-collagen interaction. | 06-13-2013 |
| 20130165380 | Administration of an antagonist of a5 1 for anti-angiogenesis and cancer treatment - The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an a5β1 antagonist with an a2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12). | 06-27-2013 |
| 20130165381 | LIPIDS, LIPID COMPLEXES AND USE THEREOF - The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I), | 06-27-2013 |
| 20130172258 | ANGIOGENESIS-INHIBITING PEPTIDE AND APPLICATION THEREOF - Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide. | 07-04-2013 |
| 20130178421 | INTERFERING RNA DELIVERY SYSTEM AND USES THEREOF - The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided. | 07-11-2013 |
| 20130184215 | PEPTIDE HAVING A VASCULARIZATION-SUPPRESSING ACTIVITY AND A USE THEREFOR - Provided are peptides having anti-angiogenic activity and a use thereof, and more particularly, to peptides for inhibiting angiogenesis, the peptides including amino acid sequence with potent anti-angiogenic activity, a composition for inhibiting angiogenesis, the composition including the peptides, a medicine for inhibiting angiogenesis, the medicine including the composition, and a method for inhibiting angiogenesis using the peptides. The peptides for inhibiting angiogenesis, the peptides including the amino acid sequence of the invention provides not only potent inhibitory activity on proliferation, migration and tube formation of vascular endothelial cells, but also potent in vivo anti-angiogenic activity and inhibitory activity on proliferation and migration of cancer cells. Therefore, the peptide for inhibiting angiogenesis can be efficaciously used as a treatment for various diseases including cancer with abnormal regulation of angiogenesis. | 07-18-2013 |
| 20130190240 | TUMOR GROWTH CONTROLLING METHOD TARGETING GALACTOSYLCERAMIDE EXPRESSION FACTOR-1 - The object of the present invention is to provide an anti-tumor agent having an anti-angiogenic effect and/or an anti-tumor growth effect or a method for tumor growth inhibition. | 07-25-2013 |
| 20130210731 | COMPOSITIONS AND METHODS TO CONTROL ANGIOGENESIS WITH CUPREDOXINS - The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development. | 08-15-2013 |
| 20130225494 | FORMULATIONS HAVING AN ALPHA V BETA 3 ANTAGONIST AND AN ALPHA 2 BETA 1 ANTAGONIST FOR ANTI-ANGIONIC THERAPY - The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an αvβ3 antagonist with an αVβ1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of echistatin and VP12 (ECL12). | 08-29-2013 |
| 20130225495 | FORMULATIONS HAVING AN ANTAGONIST OF ALPHA 5 BETA 1 FOR ANTI-ANGIOGENESIS AND CANCER TREATMENT - The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an α5β1 antagonist with an α2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12). | 08-29-2013 |
| 20130252895 | PEPTIDES OF SYNDECAN-1 FOR INHIBIT ANGIOGENESIS - The present invention provides a peptide derived from the extracellular domain of syndecan-1 that inhibits angiogenesis. | 09-26-2013 |
| 20130296242 | MEDICATION AND THERAPY TREATING OF CHOROIDAL NEOVASCULARIZATION - A medication for treating choroidal neovascularization comprises an amino acid fragment that derives from an angiogenesis inhibiting factor and comprises amino acid sequences as set forth in SEQ ID NO: 1. Moreover, a therapy of treating choroidal neovascularization by administering the said medication to an individual, with the medication comprising 0.1-1000 μg of the amino acid fragment in 1 ml solvent. | 11-07-2013 |
| 20130303456 | METHOD OF TREATING ABNORMAL ANGIOGENESIS VIA THE BAI FAMILY OF PROTEINS AND THEIR PROTEIN FRAGMENTS - The present disclosure encompasses the protein BAI1, and two cleavage products thereof, Vstat120 and Vstat40. The disclosure also describes the use of BAI1, and two cleavage products thereof, Vstat120 and Vstat40, as an anti-angiogenic and anti-tumorigenic therapy for gliomas as well as its other types of cancer and conditions involving aberrant angiogenesis. One aspect of the disclosure therefore provides a polypeptide, derived from the protein BAI1, comprising an integrin binding domain and a thrombospondin type 1 repeat. Another aspect of the disclosure provides methods of inhibiting the formation of a tumor sustained or disseminated by angiogenesis, comprising: contacting a developing tumor with one of the polypeptides derived from the protein BAI1 whereupon angiogenesis is inhibited, and thereby inhibiting the formation of the tumor. Another aspect of the disclosure is pharmaceutical compositions comprising a Vstat120 and Vstat40 polypeptide, or variants thereof, an at least one carrier for delivery to an animal or human patient. | 11-14-2013 |
| 20130316950 | MIMETIC PEPTIDES DERIVED FROM COLLAGEN TYPE IV AND THEIR USE FOR TREATING ANGIOGENESIS- AND LYMPHAGIOGENESIS-DEPENDENT DISEASES - Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties. | 11-28-2013 |
| 20130345137 | METHOD OF INHIBITING ANGIOGENESIS AND FOOD/BEVERAGE COMPOSITION FOR ANGIOGENESIS INHIBITION - A method of inhibiting angiogenesis by applying a protein polysaccharide of a (1→6)-β-D-glucan with a glucan:protein ratio of 55:43 [w/w], obtained by extracting with a 5 w % aqueous solution of sodium hydroxide a residue of extraction and removal of water-soluble polysaccharides from the | 12-26-2013 |
| 20140005113 | TREATMENT OF DISORDERS WITH ALTERED VASCULAR BARRIER FUNCTION | 01-02-2014 |
| 20140018296 | LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY - The invention provides interfering RNA molecule-ligand conjugates useful as a delivery system for delivering interfering RNA molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (LDLR) or LDLR family member. Therapeutic uses for the conjugates are also provided. | 01-16-2014 |
| 20140045757 | COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF - Compositions and methods that are useful for modulating blood vessel formation, as well as methods that provide for the systematic and efficient identification of angiogenesis modulators are described. As discussed in more detail below, a systematic computational methodology based on bioinformatics was used to identify novel peptide modulators of angiogenesis that have been characterized in vitro and/or in vivo. | 02-13-2014 |
| 20140080759 | COMPOSITIONS COMPRISING MULTIVALENT SYNTHETIC LIGANDS OF SURFACE NUCLEOLIN AND GLYCOSAMINOGLYCANS - The present invention relates to a composition comprising a Nucant multivalent synthetic compound and a glycosaminoglycan, the admixture of both compounds forming microspheres comprising both compounds, as well as their use for the treatment or prevention of diseases associated with deregulation of proliferation and/or angiogenesis, such as cancer, inflammatory disease, or for promoting wound healing. | 03-20-2014 |
| 20140088016 | MACROCYCLIC THERAPEUTIC AGENTS AND METHODS OF TREATMENT - The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders. | 03-27-2014 |
| 20140100164 | PEPTIDE MODULATORS OF ANGIOGENESIS AND USE THEREOF - The invention generally features compositions and methods that are useful for modulating blood vessel formation, as well as methods that provide for the systematic and efficient identification of angiogenesis modulators. As described in more detail below, a systematic computational methodology based on bioinformatics was used to identify novel peptide modulators of angiogenesis that have been characterized in vitro and/or in vivo. | 04-10-2014 |
| 20140107030 | POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH - In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases. | 04-17-2014 |
| 20140113865 | USE OF PERTUSSIS TOXIN AS A THERAPEUTIC AGENT - The present application relates to the use of a pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating an autoimmune disease by administering pertussis toxin to the individual. In another embodiment, the autoimmune disease is multiple sclerosis. In another embodiment, the invention provides a method of treating a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease by administering pertussis toxin, or a derivative, analog, salt or pharmaceutical equivalent. | 04-24-2014 |
| 20140121165 | Induction of the Mitochondrial Permeability Transition - The present invention relates to process for identifying a compound which induces the mitochondrial permeability transition (MPT) in proliferating cells, wherein said process comprises contacting a cell or cell extract with a compound, determining whether the compound binds to adenine nucleotide translocator (ANT), and determining whether the compound selectively induces the MPT in proliferating cells. | 05-01-2014 |
| 20140128323 | Method for prevention or treatment of diabetic angiogenesis impairment using C-peptide - Disclosed are a method and a composition for the prevention or treatment of diabetic angiogenesis impairment or diabetic wound-healing impairment, using C-peptide. Found to be able to induce angiogenesis through chemotatic migration of endothelial cells, cell migration to wounded areas, capillary-like network formation, and ERK1/2 and Akt phosphorylation and NO production, C-peptide has prophylactic or therapeutic applications in a broad spectrum of various diabetic complications including diabetic angiogenesis impairment. | 05-08-2014 |
| 20140128324 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES - The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function. | 05-08-2014 |
| 20140135267 | INTERFERING RNA DELIVERY SYSTEM AND USES THEREOF - The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided. | 05-15-2014 |
| 20140194358 | PROMININ-1 PEPTIDE FRAGMENTS AND USES THEREOF - Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration. | 07-10-2014 |
| 20140194359 | INTERFERING RNA DELIVERY SYSTEM AND USES THEREOF - The invention provides a delivery system comprising a cell penetrating peptide, 10 histidines, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided. | 07-10-2014 |
| 20140235542 | MODULAR, BIOACTIVE PEPTIDES FOR BINDING NATIVE BONE AND IMPROVING BONE GRAFT OSTEOINDUCTIVITY - A modular peptide design strategy wherein the modular peptide has two functional units separated by a spacer portion is disclosed. More particularly, the design strategy combines a bone-binding portion and a biomolecule-derived portion. The modular peptides have improved non-covalent binding to the surface of native bone, and are capable of initiating osteogenesis, angiogenesis, and/or osteogenic differentiation. | 08-21-2014 |
| 20140256635 | ANTI-ANGIOGENIC MOLECULES, NANOSTRUCTURES AND USES THEREOF - The disclosure is generally directed toward the design and synthesis of peptide amphiphile (PA) molecules that comprises a peptide configured to inhibit angiogenesis. The peptide amphiphile comprises a hydrophobic tail, peptide sequence capable of beta-sheet formation; and a peptide, wherein the peptide is configured to inhibit angiogenesis. Optionally the PA further comprises a flexible linker between the peptide sequence capable of beta-sheet formation and the peptides. Further this disclosure is directed to nanostructures comprising peptide amphiphiles configured to inhibit angiogenesis. | 09-11-2014 |
| 20140309170 | ANTI-ANGIOGENIC PEPTIDES AND USES THEREOF - Provided are peptide sequences derived from prostate serum antigen (PSA). The peptides are provided in cyclic and linear form. Methods for using the peptides for inhibition of angiogenesis, such as angiogenesis in a tumor, are provided. | 10-16-2014 |
| 20150045302 | PEPTIDES - A product comprising a peptide that comprises a motif selected from a group consisting of isoDGR, NGR and DGR, wherein the peptide cyclised by joining the N- and C-termini of its main chain and wherein the cyclic peptide is joined to albumin. | 02-12-2015 |
| 20150087589 | GENES AND PROTEINS ASSOCIATED WITH ANGIOGENESIS AND USES THEREOF - Disclosed is a panel of biomarkers associated with angiogenesis, and the use of such biomarkers (genes, proteins, homologues and analogs thereof) to regulate angiogenesis. Methods for identifying compounds useful for regulating angiogenesis and conditions related thereto are disclosed. | 03-26-2015 |
| 20150111827 | POLYPEPTIDES INHIBITING NEOVASCULARIZATION AND USES THEREOF - Provided is a polypeptide having angiogenesis inhibiting activity. The polypeptide is derived from Placenta Growth Factor-1. Also provided are a derivative polypeptide of the polypeptide, a preparation method for polypeptide, and a pharmaceutical composition containing the polypeptide. | 04-23-2015 |
| 20150119329 | MODULATION OF ANGIOTENSIN II RECEPTORS FOR THE PREVENTION AND TREATMENT OF MALARIA CEREBRAL - The present invention is directed to a composition for the treatment or prevention of cerebral malaria that comprises an angiotensin receptor type-2 agonist and an antimalaria drug. The present invention is further directed to methods for treating and preventing cerebral malaria that involve administering an angiotensin receptor type-2 agonist and/or an angiotensin receptor type-1 antagonist. | 04-30-2015 |
| 20150119330 | SUBSTRATES AND INHIBITORS OF PROLYL OLIGOPEPTIDASE AND FIBROBLAST ACTIVATION PROTEIN AND METHODS OF USE - Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as malignancies and angiogenesis, and in neural disorders such as Alzheimer's disease. Stalk portions of the inhibitor molecules, and substrates of FAP and POP, are also disclosed and may be used, for example, in screening methods for identifying such inhibitors. | 04-30-2015 |
| 20150133385 | PEPTIDE COMPOUNDS DERIVED FROM MELANOTRANSFERRIN AND USES THEREOF - Peptide compounds derived from human melanotransferrin, and compositions thereof, are described. Uses of these peptide compounds, for example to modulate angiogenesis and/or cell migration, and/or to treat angiogenesis-related disorders (e.g., cancer), are also described. | 05-14-2015 |
| 20150141340 | METHOD OF TREATING AND PREVENTING OCULAR ANGIOGENESIS - The present invention provides methods for inhibiting ocular angiogenesis, vascular leakage, and/or edema. The methods comprise administering to a subject an agent comprising a caveolin scaffolding domain. The present invention further encompasses methods of treating and/or preventing ophthalmic conditions that are associated with ocular angiogenesis, vascular leakage, or edema. | 05-21-2015 |
| 20150299258 | Peptide for Inhibiting Vascular Endothelial Growth Factor Receptor - An object of the present invention is to provide a VEGFR2 inhibitor peptide having high specificity and available at a low cost. The present invention provides a peptide having the following amino acid sequence: | 10-22-2015 |
| 20150307592 | MIMETIC PEPTIDES DERIVED FROM COLLAGEN TYPE IV AND THEIR USE FOR TREATING ANGIOGENESIS- AND LYMPHANGIOGENESIS- DEPENDENT DISEASES - Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer sonogram models and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties. | 10-29-2015 |
| 20150329591 | AZAPEPTIDES AS CD36 BINDING COMPOUNDS - An azapeptide compound of Formula I: | 11-19-2015 |
| 20150343021 | METHODS FOR TREATING CANCER USING COMPOSITIONS COMPRISING HSS1 AND/OR HSM1 - The present application relates to methods of treating cancer using compositions comprising Hematopoietic Signal peptide-containing Secreted 1 (HSS1), derivatives of HSS1. Hematopoietic Signal peptide-containing Membrane domain-containing 1 (HSM1), derivatives of HSM1, or any combination thereof. | 12-03-2015 |
| 20150344539 | BINDING PROTEINS INHIBITING THE VEGF-A RECEPTOR INTERACTION - The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration. | 12-03-2015 |
| 20150359829 | METHOD OF INHIBITING ANGIOGENESIS - A method of inhibiting angiogenesis by applying a kind of protein polysaccharide of a (1→6)-β-D-glucan obtained from a residue of extraction of crushed dried fruiting body of | 12-17-2015 |
| 20160017013 | USE OF MUTANT HAPTOGLOBIN HAVING ANGIOGENESIS PROMOTING ACTIVITY - The present invention relates to a use of mutant haptoglobin having angiogenesis-promoting activity and, more particularly, to a mutant haptoglobin polypeptide, a recombinant vector containing a polynucleotide encoding the polypeptide, or a composition for promoting angiogenesis containing, as an active ingredient, a transformant transformed with the recombinant vector. The mutant haptoglobin according to the present invention includes an amino acid sequence of SEQ ID NO: 1 in which the 143rd amino acid is substituted with an amino acid other than Arg. The mutant haptoglobin according to the present invention has excellent angiogenesis-promoting activity and excellent capillary-like tube formation capability as compared with wild-type haptoglobin, and promotes cell migration, and thus is useful as a therapeutic agent for treating diseases caused by non-angiogenesis. | 01-21-2016 |
| 20160030508 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE - Methods of inhibiting undesired angiogenesis are provided, which methods include administering to a subject a therapeutically effective amount of at least one of the compounds described herein, or a pharmaceutically acceptable salt thereof. | 02-04-2016 |
| 20160033513 | USE OF CD36 TO IDENTIFY CANCER SUBJECTS FOR TREATMENT - Provided herein are methods for identifying a subject with cancer for treatment with a Psap peptides. The subject is identified based on a level of CD36. Also provided herein are compositions and methods for treatment of a subject with cancer based on a level of CD36. | 02-04-2016 |
| 20160051526 | The Local Treatment of Inflammatory Ophthalmic Disorders - The present invention provides Nalidixic acid and analogues of Nalidixic acid, pharmaceutical compositions including at least one of Nalidixic acid and analogues of Nalidixic acid, and methods for treating inflammatory ophthalmic disorders by local administration. The ophthalmic disorders may be characterized by ocular inflammation, dry eye disorders, pathological ocular angiogenesis, or retinal or sub-retinal edema. | 02-25-2016 |
| 20160051623 | ANTI-ANGIOGENIC PEPTIDES AND USES THEREOF - Provided are peptide sequences derived from prostate serum antigen (PSA). The peptides are provided in cyclic and linear form. Methods for using the peptides for inhibition of angiogenesis, such as angiogenesis in a tumor, are provided. | 02-25-2016 |
| 20160052970 | PEPTIDOMIMETIC MACROCYCLES AND USE THEREOF IN REGULATING HIF1ALPHA - The present invention provides peptidomimetic macrocycles capable of regulating HIF1α and methods of using such macrocycles for the treatment of diseases. | 02-25-2016 |
| 20160068527 | The Treatment of Inflammatory Disorders - The present invention provides Nalidixic acid and analogues of Nalidixic acid, and methods for treating inflammatory disorders. The Nalidixic acid and analogues of Nalidixic acid may be formulated for topical delivery or systemic delivery. The inflammatory disorders that may be treated with the Nalidixic acid and analogues of Nalidixic acid include respiratory diseases, chronic degenerative diseases, dematological conditions, chronic demyelinating diseases, dental diseases, ophthalmic conditions, inflammatory bowel diseases, and graft versus host diseases. | 03-10-2016 |
| 20160068579 | Trap 63 - The present invention for the first time discloses a novel small molecular weight enamel matrix polypeptide which is at least 80%, such as 90% identical to the amino acid sequence as shown in SEQ ID NO: 1 (MPLPPHPGHP GYINFSYEVL TPLKWYQNMI RHPYTSYGYE PMGGWLHHQI IPWSQQTPQ SHA) (TRAP63), a homologue, analogue, or a pharmaceutically acceptable salt thereof. The present invention further discloses a pharmaceutical composition consisting of an enamel matrix polypeptide which is at least 80%, such as 90% identical to the amino acid sequence as shown in SEQ ID NO: 1, a homologue, analogue, or a pharmaceutically acceptable salt thereof, and a suitable pharmaceutical carrier, which further can consist of one or more enamel matrix polypeptides selected from the group of enamel matrix polypeptides which correspond to: a. SEQ ID NO: 2, b. SEQ ID NO: 3 and c. SEQ ID NO: 4. | 03-10-2016 |
| 20160082083 | METHOD OF INHIBITING ANGIOGENESIS, TUMORIGENESIS AND CATHEPSIN ACTIVITY - Insulin-like growth factor binding proteins (IGFBPs) and variants thereof, including IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, IGFBP-8 and the C-terminal fragments thereof, inhibit angiogenesis, tumorigenesis and cathepsin activity, particularly cathepsin B activity. | 03-24-2016 |
| 20160090408 | ANTI-ANGIOGENIC AGENT AND METHODS OF USING SUCH AGENT - Anti-angiogenic agents or polypeptides comprising an amino acid segment substantially similar to domain one of CD2 wherein the polypeptide has a β-sheet formed by two segments. Methods of using such agents and polypeptide are also included. | 03-31-2016 |
| 20160108088 | ANTI-ANGIOGENIC MOLECULES, NANOSTRUCTURES AND USES THEREOF - The disclosure is generally directed toward the design and synthesis of peptide amphiphile (PA) molecules that comprises a peptide configured to inhibit angiogenesis. The peptide amphiphile comprises a hydrophobic tail, peptide sequence capable of beta-sheet formation; and a peptide, wherein the peptide is configured to inhibit angiogenesis. Optionally the PA further comprises a flexible linker between the peptide sequence capable of beta-sheet formation and the peptides. Further this disclosure is directed to nanostructures comprising peptide amphiphiles configured to inhibit angiogenesis. | 04-21-2016 |
| 20160151448 | MULTIMERIC TIE 2 AGONISTS AND USES THEREOF IN STIMULATING ANGIOGENESIS | 06-02-2016 |
| 20160194380 | POTENT INHIBITORS OF HUMAN MATRIPTASE DERIVED FROM MCOTI-II VARIANTS | 07-07-2016 |
| 20160375145 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY - The invention relates to improvements in the field of drug delivery. More particularly, the invention relates to polypeptides having a hydrolyzable covalent bond to a therapeutic agent that includes, etoposide, etoposide 4′-dimethylglycine or doxorubicin. These polypeptide conjugates can be used as vectors to transport the podophyllotoxin derivative across the blood brain barrier (BBB) or into particular cell types such as ovary, liver, lung, or kidney. The invention also relates to pharmaceutical compositions that include the compounds of the invention and to uses thereof in methods of treatment. | 12-29-2016 |
